Latest news with #genetictesting
Yahoo
17 hours ago
- Business
- Yahoo
Tempus AI shares leap on forecast-beating results, revenue guidance
-- Tempus AI (NASDAQ:TEM) surged 9% in premarket trading Friday after the genetic testing firm reported a second-quarter loss per share of $0.22, better than the $0.25 loss expected by analysts. Revenue for the period came in at $314.6 million, ahead of the $297.8 million consensus estimate. Genomics revenue surged 115.3% year-on-year to $241.8 million, driven by accelerating volume growth in Oncology testing, up 26%, and Hereditary testing, up 32%. Data and services revenue rose 35.7% to $72.8 million, supported by a 40.7% increase in Insights, the company's data licensing business. 'The business is performing well with revenues and margins growing faster than expected, contributing to our continued improvement in adjusted EBITDA on a year-over-year basis,' said Eric Lefkofsky, Founder and CEO of Tempus. 'We saw significant re-acceleration of our clinical volumes which grew 30% in the quarter, as we delivered more than 212,000 NGS tests. Combined with our continued leadership in AI and progress toward building the largest foundation model in oncology, 'we're hitting our stride' as we approach our 10th anniversary.' For full-year 2025, Tempus now expects revenue of $1.26 billion, up from its prior forecast of $1.25 billion and above the $1.248 billion consensus. Adjusted EBITDA is projected at $5 million, an improvement of roughly $110 million from 2024. Related articles Tempus AI shares leap on forecast-beating results, revenue guidance These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia 7 Undervalued Stocks on the Rise With 50%+ Upside Potential
Yahoo
2 days ago
- Business
- Yahoo
Why Is Myriad Genetics (MYGN) Stock Soaring Today
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 36.4% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year revenue forecast. The genetic testing firm announced revenue of $213.1 million, which sailed past analyst estimates of around $202 million. It also posted an adjusted profit of $0.05 per share, a significant turnaround from the minor loss that experts had predicted. A key driver for this outperformance was the company's hereditary cancer testing business, which grew 9% compared to the previous year. Bolstered by this momentum, Myriad Genetics lifted its full-year revenue guidance to a range of $818 million to $828 million and secured a new $200 million credit facility to fund its growth. Is now the time to buy Myriad Genetics? Access our full analysis report here, it's free. What Is The Market Telling Us Myriad Genetics's shares are extremely volatile and have had 35 moves greater than 5% over the last year. But moves this big are rare even for Myriad Genetics and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 8 days ago when the stock dropped 3.8% on the news that weakness in the healthcare sector became pronounced following a poor sales report from a key competitor. The negative sentiment was partly fueled by health insurance giant UnitedHealth Group, which reported a miss on its second-quarter earnings and issued a profit warning, casting a pall over the entire sector. More directly, NeoGenomics, a company also operating in the cancer diagnostics space, reported that it had missed its second-quarter sales targets. This news, which sent NeoGenomics' stock down significantly, suggested a potentially more challenging market environment for companies involved in oncology diagnostics, a core business for Myriad Genetics. Myriad Genetics is down 58.8% since the beginning of the year, and at $5.56 per share, it is trading 80.5% below its 52-week high of $28.60 from September 2024. Investors who bought $1,000 worth of Myriad Genetics's shares 5 years ago would now be looking at an investment worth $449.06. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Sign in to access your portfolio
Fox News
3 days ago
- Politics
- Fox News
Trump says there will be 'some form of testing' for women's sports at 2028 LA Olympics
President Donald Trump responds to a question about genetic testing for women's athletes at the 2028 Los Angeles Olympics, saying there will be a "strong form of testing." (White House)
The National
4 days ago
- Health
- The National
Genetic test can improve cancer care and cut side effects
Medical researchers in the UAE are turning to genetic testing to understand more about how some patients respond to drugs so that side effects can be reduced and effectiveness improved. Pharmacogenetics is becoming more common in the treatment of cancer, depression and cardiac disease. More personalised prescriptions, rather than a one size fits all approach to medication, can improve patient care and cut costs for hospital and insurers, researchers said. Genetics play a significant role in drug response, with an estimated 70–90 per cent of drug response variability having a genetic component. More than 200 medications – including drugs for oncology, cardiology, psychiatry, pain management, and infectious diseases – come with guidelines that advise prescribing based on a person's genes. Tests costs around Dh1,000 but that is expected to come down in price as doctors predict they will become a routine aspect of care. Jen Blandos, 51, a Canadian, had a first breast cancer diagnosis in 2012 and two more cancer diagnoses after that. Her latest breast cancer treatment plan has been created using knowledge gleaned by doctors from a genetic test, allowing them to improve her care and minimise debilitating side effects of regular chemotherapy. 'Compared to my first cancer diagnosis, now there's much more detailed mapping of the cancer I have, and a number of different things doctors look at to determine the best treatment,' said Ms Blandos, who lives in Dubai and has two children. 'One of the tests is getting more comprehensive mapping done on my genes. I had genetic variants where it showed I don't metabolise certain drugs. I also have a tonne of allergies, including all opiates and pain relief except paracetamol," she said. 'I'm also allergic to all antibiotics except for one, so I'm not an easy person for doctors to treat. 'When you're put on drugs for seven years after chemotherapy, you want to make sure it's going to be the right drug and it's going to work.' Tumour test score Her most recently discovered cancer, an invasive carcinoma, was picked up in a routine check in April. Doctors took a blood test and biopsy of her tumour to understand more about the kind of care she would most respond to. The test is based on the activity of 21 genes in the tumour tissue and gives an indication of how likely the cancer will respond to chemotherapy, or return in the future. It helped doctors decide on 12 courses of chemotherapy. 'Like anybody who's had cancer, universally we all worry about it returning,' said Ms Blandos. 'We try to put it to the back of our minds. I'm aware there is potential for genetic data to be misused, and there could be future problems. 'But I know the genetic testing that I need allows insurers to have access to that information, which makes me cheaper as a patient for them as they're not wasting money on treatments I don't necessarily need.' There is particular value to genetic testing of patients with chronic health conditions who are prescribed multiple medications. Personalised medicine is becoming more common in every-day care. Ravi Sharma, chief pharmacy officer at Burjeel Holdings, said genetic testing could become a routine part of prescriptions. 'Medicines are one of the most common interventions in healthcare, and what's really interesting is that from the evidence, 30 to 60 per cent of patients may not always respond commonly as we predict to these medicines,' he said. 'We would like this to be a pre-test for patients getting their routine care, to enable us throughout their whole healthcare journey to prescribe optimally according to their genomic response.' Within 20 years, more than 90 per cent of patient populations across the world will find at least one drug that has a pharmaco-genomic gene relationship, doctors said. Treatments could be optimised in a number of fields, such as psychiatry, hypertension, endocrinology, opioid use and management, and oncology. Hassan Jaafar, consultant in medical oncology and medical director at Burjeel Cancer Institute, said pharmaco-genomics is playing a major role in his clinical management. 'Even within the same ethnicity, there are different hereditary backgrounds which make certain drugs metabolise faster in the liver, and even in other parts of the tissue,' he said. 'It's important to identify the sensitivity and the toxicity of chemotherapeutic agents or any other drugs. 'The approach for those patients, the outcome, the prognosis can be completely different if you identify them and approach them differently to the standard treatment.' More efficient prescribing Genetic testing can also streamline prescribing to reduce hospital admissions with better use of medicines, allowing doctors to deliver more sustained continuity of care. A typical test involves a blood sample processed in a lab, with the genetic information integrated into a patient's health records. When a doctor comes to prescribe medication, they would receive an alert displaying a patient's clinical parameters and suitability for drugs. Mohammad Fityan, chief medical officer at Burjeel Medical City, said patients currently have to pay for the Dh1000 test, but it could soon become available under health insurance. 'By doing this test, not only we will make sure that the medicine will work, but it will work safely and with fewer side effects,' he said. 'In patients with depression, we can try some medication and it takes us up to six weeks before we know whether it will work effectively or not. 'We have all these drug resources, now it's about how to use them effectively in a smart way that will serve our patients the best.'
The National
4 days ago
- Health
- The National
Doctors turn to genetic tests to improve cancer care and cut side effects
Medical researchers in the UAE are turning to genetic testing to understand more about how some patients respond to drugs so that side effects can be reduced and effectiveness improved. Pharmacogenetics is becoming more common in the treatment of cancer, depression and cardiac disease. More personalised prescriptions, rather than a one size fits all approach to medication, can improve patient care and cut costs for hospital and insurers, researchers said. Genetics play a significant role in drug response, with an estimated 70–90 per cent of drug response variability having a genetic component. More than 200 medications – including drugs for oncology, cardiology, psychiatry, pain management, and infectious diseases – come with guidelines that advise prescribing based on a person's genes. Tests costs around Dh1,000 but that is expected to come down in price as doctors predict they will become a routine aspect of care. Jen Blandos, 51, a Canadian, had a first breast cancer diagnosis in 2012 and two more cancer diagnoses after that. Her latest breast cancer treatment plan has been created using knowledge gleaned by doctors from a genetic test, allowing them to improve her care and minimise debilitating side effects of regular chemotherapy. 'Compared to my first cancer diagnosis, now there's much more detailed mapping of the cancer I have, and a number of different things doctors look at to determine the best treatment,' said Ms Blandos, who lives in Dubai and has two children. 'One of the tests is getting more comprehensive mapping done on my genes. I had genetic variants where it showed I don't metabolise certain drugs. I also have a tonne of allergies, including all opiates and pain relief except paracetamol," she said. 'I'm also allergic to all antibiotics except for one, so I'm not an easy person for doctors to treat. 'When you're put on drugs for seven years after chemotherapy, you want to make sure it's going to be the right drug and it's going to work.' Tumour test score Her most recently discovered cancer, an invasive carcinoma, was picked up in a routine check in April. Doctors took a blood test and biopsy of her tumour to understand more about the kind of care she would most respond to. The test is based on the activity of 21 genes in the tumour tissue and gives an indication of how likely the cancer will respond to chemotherapy, or return in the future. It helped doctors decide on 12 courses of chemotherapy. 'Like anybody who's had cancer, universally we all worry about it returning,' said Ms Blandos. 'We try to put it to the back of our minds. I'm aware there is potential for genetic data to be misused, and there could be future problems. 'But I know the genetic testing that I need allows insurers to have access to that information, which makes me cheaper as a patient for them as they're not wasting money on treatments I don't necessarily need.' There is particular value to genetic testing of patients with chronic health conditions who are prescribed multiple medications. Personalised medicine is becoming more common in every-day care. Ravi Sharma, chief pharmacy officer at Burjeel Holdings, said genetic testing could become a routine part of prescriptions. 'Medicines are one of the most common interventions in healthcare, and what's really interesting is that from the evidence, 30 to 60 per cent of patients may not always respond commonly as we predict to these medicines,' he said. 'We would like this to be a pre-test for patients getting their routine care, to enable us throughout their whole healthcare journey to prescribe optimally according to their genomic response.' Within 20 years, more than 90 per cent of patient populations across the world will find at least one drug that has a pharmaco-genomic gene relationship, doctors said. Treatments could be optimised in a number of fields, such as psychiatry, hypertension, endocrinology, opioid use and management, and oncology. Hassan Jaafar, consultant in medical oncology and medical director at Burjeel Cancer Institute, said pharmaco-genomics is playing a major role in his clinical management. 'Even within the same ethnicity, there are different hereditary backgrounds which make certain drugs metabolise faster in the liver, and even in other parts of the tissue,' he said. 'It's important to identify the sensitivity and the toxicity of chemotherapeutic agents or any other drugs. 'The approach for those patients, the outcome, the prognosis can be completely different if you identify them and approach them differently to the standard treatment.' More efficient prescribing Genetic testing can also streamline prescribing to reduce hospital admissions with better use of medicines, allowing doctors to deliver more sustained continuity of care. A typical test involves a blood sample processed in a lab, with the genetic information integrated into a patient's health records. When a doctor comes to prescribe medication, they would receive an alert displaying a patient's clinical parameters and suitability for drugs. Mohammad Fityan, chief medical officer at Burjeel Medical City, said patients currently have to pay for the Dh1000 test, but it could soon become available under health insurance. 'By doing this test, not only we will make sure that the medicine will work, but it will work safely and with fewer side effects,' he said. 'In patients with depression, we can try some medication and it takes us up to six weeks before we know whether it will work effectively or not. 'We have all these drug resources, now it's about how to use them effectively in a smart way that will serve our patients the best.'
